Moderna maintains that the corporate supplied the wanted management comparability for older individuals. “The letter is inconsistent with earlier written communications from CBER to Moderna,” the corporate stated in an announcement. The corporate additionally says “CBER didn’t increase any objections or medical maintain feedback concerning the adequacy of the Section 3 trial after the submission of the protocol in April 2024 or at any time earlier than the initiation of the research in September 2024.”
Support Greater and Subscribe to view content
This is premium stuff. Subscribe to read the entire article.
Login if you have purchased
